<DOC>
	<DOCNO>NCT01670032</DOCNO>
	<brief_summary>This study multicenter , randomize , vehicle control , parallel , group , double blind study . Eligible subject clinical diagnosis impetigo randomize one four treatment group : 1.5 % CD07223 Topical Gel apply BID ; 1.5 % CD07223 Topical Gel apply TID ; Vehicle Topical Gel apply BID ; Vehicle Topical Gel apply TID . All treatment administer 7 day . Disease activity Target Lesion evaluate use Skin Infection Rating Scale ( SIRS ) Score .</brief_summary>
	<brief_title>Vehicle Controlled Efficacy Safety Study Two Dose Regimens CD07223 1.5 % Topical Gel Impetigo</brief_title>
	<detailed_description />
	<mesh_term>Impetigo</mesh_term>
	<criteria>Male female 2 year age old Clinical diagnosis primary impetigo ( bullous non bullous ) Minimum diameter Target Lesion one centimeter measure either length width . Presence least one ten lesion per subject time screen The infected lesion ' total area ( determined Investigator ) must less 100 cm2 total area subject 18 year age old , maximum 2 % total body surface area subject young 18 year age . Skin Infection Rating Scale ( SIRS ) total score Target Lesion least 4 Presence active skin disease near Target Lesion area treat A subject whose disease widespread severe , opinion investigator , oral antibiotic treatment need Signs symptom another current infection require antibiotic treatment Tympanic temperature Screening/Baseline exceed 38 degree Celsius ( 100.4 degree Fahrenheit ) pediatric subject 37.8 degree Celsius ( 100 degree Fahrenheit ) adult subject History Hepatitis B C , HIV/ AIDS , immunodeficiency disease Concurrent recent scabies infection louse infestation ( pediculosis ) scalp Use systemic antibiotic systemic steroid within 14 day prior study entry . A history three course systemic antibiotic within 3 month period immediately prior screening also consider exclusionary Use topical antibiotic , topical antibacterial , topical antifungal topical steroid within 14 day prior study entry skin lesion ( deem significant Investigator virtue lesion 's nature and/or position impact effectiveness study drug ) Participation clinical study use investigational drug investigational device within 30 day prior enrollment Presence secondarily infect traumatic lesion ( e.g . surgical wound , animal/insect bite , burn , laceration abrasion ) . Another family member household currently enrol study another family member household active impetigo</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>